Terry Faleye, MPAS, PA-C

Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.

Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.

Panelists discuss how novel treatment mechanisms, efficacy assessments, and improved patient engagement strategies are shaping the evolving landscape of vitiligo management.

Panelists discuss how to address treatment challenges and manage site-specific concerns in vitiligo patients, drawing on expert insights and clinical experience.

Panelists discuss how phototherapy, combination treatments, and patient-centered strategies can be utilized to enhance quality of life for individuals with vitiligo.

Panelists discuss how to improve treatment adherence, incorporate adjunctive therapies, and simplify complex regimens for patients with vitiligo through case-based analysis.

Panelists discuss how vitiligo treatment delays, psychosocial effects, and emerging therapies impact standard of care for patients through case-based analysis.

Psoriasis specialists evaluate strategies for integrating emerging therapies into existing treatment protocols and conclude by addressing persistent gaps in current psoriasis management approaches.

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Clinicians analyze long-term efficacy data in psoriasis treatments, focusing on how they communicate and contextualize information about treatment duration to their patients.

Physicians examine the enduring effectiveness and key findings from the POETYK PSO-1 clinical trials, evaluating their impact on the evolving landscape of psoriasis treatment options.

Medical experts explore approaches for addressing suboptimal outcomes in systemic psoriasis treatments, including methods to enhance therapeutic efficacy and criteria for transitioning to alternative treatments.

Dermatology experts examine the role of IL-17 inhibitors in psoriasis management, focusing on treatment strategies, swift clinical responses, and their effectiveness across various anatomical sites affected by plaque psoriasis.

Medical professionals discuss ongoing clinical trials and novel medications for the treatment of psoriasis.

Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

Key opinion leaders examine patient response rates to biologic treatments and provide critical insights on transitioning between therapies to optimize patient outcomes.

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Key opinion leaders explore the management of plaque psoriasis, addressing treatment-related challenges and emphasizing the importance of effective communication for informed decision-making in therapy selection.

The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.

Medical experts specializing in plaque psoriasis offer a comprehensive overview of the current treatment landscape, its evolution, and the disease's psychological and physical impacts.

Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.

Experts in dermatology review unmet needs in the plaque psoriasis treatment landscape, as well as ongoing studies coming down the pipeline.

Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.

Experts in dermatological conditions review the case of a 40-year-old female with a long history of plaque psoriasis, highlighting the psychosocial impact of the disease and the importance of multidisciplinary care.

Lakshi Aldredge, MSN, ANP-BC, comments on the role of nurse practitioners and physician assistants in plaque psoriasis treatment management. Jennifer Conner, MPAS, PA-C, reviews the long-term considerations with systemic therapy.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Dermatology experts discuss the use of systemic therapy in plaque psoriasis and determining patient response to treatment, also commenting on the use of PASI scoring in the clinical setting.

Jennifer Conner, MPAS, PA-C, and Terry Faleye, MPAS, PA-C, review a case of a young adult female with plaque psoriasis on the elbows, thighs, and scalp, and discuss switching systemic treatments to accommodate her lifestyle.